Radient Pharmaceuticals Corporation AMEX:RPC on December 20, 2010 surged 56.55% to the closing price of $0.58. The overall volume in the last trading session was 5.43 million shares. Its fifty two week range was $0.20- $2.59. The total market capitalization remained $ 21.32 million.
The stock price of RPC is moving above its 20 days moving average with 50.65% and ahead from 50 days moving average with 23.93%. RPC quarter performance reduced with 14.71% while the current year earnings per share also experienced reduction of 1538.09%.
RPC is above its 52 week low with 190% and below from 52 week high price with 77.61%. RPC last month stock price volatility remained 15.13% and its beta coefficient included 0.91. In its share capital RPC has 36.76 million outstanding shares among them 34.94 million shares have been floated in market exchange. RPC stock institutional ownership remained 5.54%.
Radient Pharmaceuticals Corporation is a vertically integrated pharmaceutical company. The Company is engaged in development, manufacture and marketing of advanced medical diagnostic products, including its ONKO-SURE, a in-vitro diagnostic (IVD) cancer test. The ONKO-SURE test kit is a tumor-marker, which is a biochemical substance indicative of neoplasia, sensitive, and proportional to tumor load, used to screen, diagnose, assess prognosis, follow response to treatment, and monitor for recurrence. As ONKO-SURE test kit is a non-invasive blood test. The ONKO-SURE test kit can be added easily and inexpensively to the pre-existing line of ELISA-based diagnostics performed routinely by clinical laboratories throughout the world. In June 2009, the Company sold its interest in Yangbian Yiqiao Bio-Chemical Pharmacy Company Limited ).
No comments:
Post a Comment